Activity of gemifloxacin against Streptococcus pneumoniae and Haemophilus influenzae

被引：10
作者：
Morrissey, I
Tillotson, G
机构：
[1] GR Micro Ltd, London NW1 3ER, England
[2] Publ Hlth Res Inst, Newark, NJ USA
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2004年 / 53卷 / 02期
关键词：
fluoroquinolones; respiratory tract infections; fluoroquinolone resistance; community-acquired pneumonia; acute exacerbation of chronic bronchitis;
D O I：
10.1093/jac/dkh092
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
This review focuses on the activity of gemifloxacin, a new respiratory fluoroquinolone, against the two most important bacterial pathogens associated with lower respiratory tract infections, namely Streptococcus pneumoniae and Haemophilus influenzae.
引用
收藏
页码：144 / 148
页数：5
相关论文
共 69 条
[1]   Streptococcus pneumoniae isolates with reduced susceptibility to ciprofloxacin in Spain:: Clonal diversity and appearance of ciprofloxacin-resistant epidemic clones [J].
Alou, L ;
Ramirez, M ;
García-Rey, C ;
Prieto, J ;
de Lencastre, H .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2955-2957
[2]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[3]   Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia [J].
Anderson, KB ;
Tan, JS ;
File, TM ;
DiPersio, JR ;
Willey, BM ;
Low, DE .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (03) :376-381
[4]   ANTIMICROBIAL RESISTANCE IN STREPTOCOCCUS-PNEUMONIAE - AN OVERVIEW [J].
APPELBAUM, PC .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (01) :77-83
[5]   LOWER RESPIRATORY-TRACT INFECTION THERAPY - THE ROLE OF CIPROFLOXACIN [J].
BALL, AP ;
TILLOTSON, GS .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1995, 23 (05) :315-327
[6]   EPIDEMIOLOGY AND TREATMENT OF CHRONIC-BRONCHITIS AND ITS EXACERBATIONS [J].
BALL, P .
CHEST, 1995, 108 (02) :S43-S52
[7]   Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections [J].
Ball, P ;
File, TM ;
Twynholm, M ;
Henkel, T .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (01) :19-27
[8]   Efficacy of gemifloxacin in acute exacerbations of chromic bronchitis: a randomised, double-blind comparison with trovafloxacin [J].
Ball, P ;
Wilson, R ;
Mandell, L ;
Brown, J ;
Henkel, T .
JOURNAL OF CHEMOTHERAPY, 2001, 13 (03) :288-298
[9]   CIPROFLOXACIN-RESISTANT HAEMOPHILUS-INFLUENZAE INFECTION IN A PATIENT WITH CHRONIC LUNG-DISEASE [J].
BARRIERE, SL ;
HINDLER, JA .
ANNALS OF PHARMACOTHERAPY, 1993, 27 (03) :309-310
[10]   Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection [J].
Berry, V ;
Page, R ;
Satterfield, J ;
Singley, C ;
Straub, R ;
Woodnutt, G .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 :79-85
1234567